West Stock Based Compensation from 2010 to 2025

WST Stock

USD 232.34 9.78 4.39%

West Pharmaceutical Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation will likely drop to about 12.5 M in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2008-06-30

Previous Quarter

5.1 M

Current Value

4.3 M

Quarterly Volatility

2.8 M

Credit Downgrade

Yuan Drop

Covid

Check West Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among West Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 163.2 M, Total Revenue of 3 B or Gross Profit of 1 B, as well as many indicators such as Price To Sales Ratio of 8.68, Dividend Yield of 0.0023 or PTB Ratio of 9.36. West financial statements analysis is a perfect complement when working with West Pharmaceutical Valuation or Volatility modules.

Check out the analysis of West Pharmaceutical Correlation against competitors.

Latest West Pharmaceutical's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of West Pharmaceutical Services over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. West Pharmaceutical's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in West Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

West Stock Based Compensation Regression Statistics

	Arithmetic Mean	19,953,938
	Geometric Mean	16,641,881
	Coefficient Of Variation	45.71
	Mean Deviation	6,752,805
	Median	19,500,000
	Standard Deviation	9,121,156
	Sample Variance	83.2T
	Range	36.3M
	R-Value	0.44
	Mean Square Error	71.5T
	R-Squared	0.20
	Significance	0.08
	Slope	851,684
	Total Sum of Squares	1247.9T

West Stock Based Compensation History

	2025	12.5 M
	2024	18.7 M
	2023	23.3 M
	2022	23.7 M
	2021	37.5 M
	2020	34 M
	2019	24.4 M

Other Fundumenentals of West Pharmaceutical

Stock Based Compensation To Revenue

West Pharmaceutical Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	-0.78	0.95	0.98	0.78	0.97	0.34	-0.43	0.98	0.57	-0.46	0.47	-0.87	0.96	0.18	0.88	0.95	-0.62	0.52	0.65	0.85	-0.93	0.59	0.88	0.92	0.9	-0.5
Total Stockholder Equity	0.98		-0.84	0.97	0.99	0.69	0.98	0.33	-0.56	0.97	0.58	-0.58	0.36	-0.92	0.96	0.08	0.87	0.98	-0.7	0.59	0.64	0.86	-0.96	0.59	0.9	0.94	0.92	-0.51
Net Debt	-0.78	-0.84		-0.73	-0.8	-0.45	-0.89	-0.37	0.65	-0.78	-0.52	0.73	-0.08	0.87	-0.67	0.07	-0.76	-0.78	0.67	-0.58	-0.64	-0.86	0.91	-0.25	-0.85	-0.86	-0.92	0.1
Retained Earnings	0.95	0.97	-0.73		0.97	0.68	0.9	0.26	-0.6	0.93	0.46	-0.56	0.26	-0.92	0.96	0.1	0.86	0.99	-0.63	0.48	0.63	0.77	-0.89	0.74	0.88	0.93	0.86	-0.68
Net Receivables	0.98	0.99	-0.8	0.97		0.73	0.97	0.26	-0.54	0.98	0.56	-0.51	0.38	-0.91	0.97	0.14	0.89	0.98	-0.67	0.57	0.66	0.86	-0.96	0.58	0.9	0.92	0.9	-0.56
Total Liab	0.78	0.69	-0.45	0.68	0.73		0.74	0.15	0.02	0.75	0.19	0.03	0.5	-0.6	0.68	0.68	0.79	0.66	-0.03	0.01	0.75	0.7	-0.61	0.45	0.69	0.72	0.71	-0.38
Total Current Assets	0.97	0.98	-0.89	0.9	0.97	0.74		0.36	-0.47	0.96	0.58	-0.53	0.4	-0.9	0.9	0.16	0.87	0.92	-0.64	0.55	0.69	0.9	-0.97	0.47	0.91	0.94	0.96	-0.35
Short Term Debt	0.34	0.33	-0.37	0.26	0.26	0.15	0.36		-0.08	0.32	0.17	-0.51	0.22	-0.31	0.24	-0.07	0.13	0.23	-0.27	0.17	0.21	0.23	-0.31	0.31	0.27	0.35	0.31	0.15
Intangible Assets	-0.43	-0.56	0.65	-0.6	-0.54	0.02	-0.47	-0.08		-0.45	-0.2	0.83	0.47	0.73	-0.46	0.42	-0.52	-0.65	0.63	-0.5	-0.35	-0.48	0.59	-0.41	-0.57	-0.59	-0.55	0.44
Accounts Payable	0.98	0.97	-0.78	0.93	0.98	0.75	0.96	0.32	-0.45		0.62	-0.48	0.48	-0.85	0.96	0.13	0.87	0.94	-0.67	0.61	0.65	0.87	-0.95	0.55	0.87	0.88	0.86	-0.49
Common Stock	0.57	0.58	-0.52	0.46	0.56	0.19	0.58	0.17	-0.2	0.62		-0.29	0.58	-0.35	0.62	-0.23	0.35	0.48	-0.77	0.85	0.13	0.55	-0.64	0.08	0.48	0.4	0.39	0.0
Long Term Debt	-0.46	-0.58	0.73	-0.56	-0.51	0.03	-0.53	-0.51	0.83	-0.48	-0.29		0.27	0.7	-0.43	0.49	-0.45	-0.59	0.68	-0.53	-0.33	-0.5	0.63	-0.41	-0.56	-0.6	-0.57	0.18
Good Will	0.47	0.36	-0.08	0.26	0.38	0.5	0.4	0.22	0.47	0.48	0.58	0.27		-0.04	0.49	0.34	0.16	0.22	-0.22	0.32	0.07	0.27	-0.34	0.02	0.18	0.17	0.18	0.0
Treasury Stock	-0.87	-0.92	0.87	-0.92	-0.91	-0.6	-0.9	-0.31	0.73	-0.85	-0.35	0.7	-0.04		-0.82	-0.09	-0.86	-0.95	0.58	-0.43	-0.74	-0.83	0.89	-0.57	-0.93	-0.96	-0.94	0.48
Property Plant Equipment	0.96	0.96	-0.67	0.96	0.97	0.68	0.9	0.24	-0.46	0.96	0.62	-0.43	0.49	-0.82		0.1	0.79	0.95	-0.7	0.6	0.53	0.75	-0.9	0.62	0.81	0.84	0.79	-0.63
Current Deferred Revenue	0.18	0.08	0.07	0.1	0.14	0.68	0.16	-0.07	0.42	0.13	-0.23	0.49	0.34	-0.09	0.1		0.18	0.07	0.57	-0.52	0.55	0.12	0.01	0.06	0.2	0.2	0.2	-0.02
Short Term Investments	0.88	0.87	-0.76	0.86	0.89	0.79	0.87	0.13	-0.52	0.87	0.35	-0.45	0.16	-0.86	0.79	0.18		0.89	-0.45	0.41	0.74	0.93	-0.86	0.51	0.88	0.89	0.88	-0.5
Net Tangible Assets	0.95	0.98	-0.78	0.99	0.98	0.66	0.92	0.23	-0.65	0.94	0.48	-0.59	0.22	-0.95	0.95	0.07	0.89		-0.66	0.53	0.65	0.82	-0.92	0.67	0.9	0.93	0.89	-0.64
Long Term Debt Total	-0.62	-0.7	0.67	-0.63	-0.67	-0.03	-0.64	-0.27	0.63	-0.67	-0.77	0.68	-0.22	0.58	-0.7	0.57	-0.45	-0.66		-0.91	-0.1	-0.55	0.75	-0.29	-0.55	-0.53	-0.53	0.28
Capital Surpluse	0.52	0.59	-0.58	0.48	0.57	0.01	0.55	0.17	-0.5	0.61	0.85	-0.53	0.32	-0.43	0.6	-0.52	0.41	0.53	-0.91		0.05	0.57	-0.71	0.04	0.44	0.37	0.39	-0.13
Deferred Long Term Liab	0.65	0.64	-0.64	0.63	0.66	0.75	0.69	0.21	-0.35	0.65	0.13	-0.33	0.07	-0.74	0.53	0.55	0.74	0.65	-0.1	0.05		0.76	-0.61	0.39	0.84	0.8	0.77	-0.18
Long Term Investments	0.85	0.86	-0.86	0.77	0.86	0.7	0.9	0.23	-0.48	0.87	0.55	-0.5	0.27	-0.83	0.75	0.12	0.93	0.82	-0.55	0.57	0.76		-0.91	0.29	0.91	0.87	0.88	-0.2
Accumulated Depreciation	-0.93	-0.96	0.91	-0.89	-0.96	-0.61	-0.97	-0.31	0.59	-0.95	-0.64	0.63	-0.34	0.89	-0.9	0.01	-0.86	-0.92	0.75	-0.71	-0.61	-0.91		-0.4	-0.88	-0.89	-0.91	0.37
Short Long Term Debt	0.59	0.59	-0.25	0.74	0.58	0.45	0.47	0.31	-0.41	0.55	0.08	-0.41	0.02	-0.57	0.62	0.06	0.51	0.67	-0.29	0.04	0.39	0.29	-0.4		0.51	0.61	0.43	-0.76
Cash And Equivalents	0.88	0.9	-0.85	0.88	0.9	0.69	0.91	0.27	-0.57	0.87	0.48	-0.56	0.18	-0.93	0.81	0.2	0.88	0.9	-0.55	0.44	0.84	0.91	-0.88	0.51		0.97	0.93	-0.32
Net Invested Capital	0.92	0.94	-0.86	0.93	0.92	0.72	0.94	0.35	-0.59	0.88	0.4	-0.6	0.17	-0.96	0.84	0.2	0.89	0.93	-0.53	0.37	0.8	0.87	-0.89	0.61	0.97		0.97	-0.41
Net Working Capital	0.9	0.92	-0.92	0.86	0.9	0.71	0.96	0.31	-0.55	0.86	0.39	-0.57	0.18	-0.94	0.79	0.2	0.88	0.89	-0.53	0.39	0.77	0.88	-0.91	0.43	0.93	0.97		-0.31
Capital Stock	-0.5	-0.51	0.1	-0.68	-0.56	-0.38	-0.35	0.15	0.44	-0.49	0.0	0.18	0.0	0.48	-0.63	-0.02	-0.5	-0.64	0.28	-0.13	-0.18	-0.2	0.37	-0.76	-0.32	-0.41	-0.31

Click cells to compare fundamentals

About West Pharmaceutical Financial Statements

West Pharmaceutical shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although West Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. The changes in West Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses on on West Pharmaceutical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	18.7 M	12.5 M
Stock Based Compensation To Revenue	0.01	0.01

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

West Stock Based Compensation from 2010 to 2025

Latest West Pharmaceutical's Stock Based Compensation Growth Pattern

West Stock Based Compensation Regression Statistics

West Stock Based Compensation History

Other Fundumenentals of West Pharmaceutical

West Pharmaceutical Stock Based Compensation component correlations

About West Pharmaceutical Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for West Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY